Neuroprotective peptide MTFL457 could be important for stroke treatment in humans because, in a preclinical stroke model, it not only counteracts TrkB-FL downregulation, decreases infarct size, and improves neurological outcome [8] but also inhibits GA fragmentation. This evidence concerns the gene NTRK2 and stroke disorder.